Biodosimetry, can it find its way to the nuclear medicine clinic?

Julie Bolcaen; Nastassja Combrink; Kaat Spoormans; Stuart More; Charlot Vandevoorde; Randall Fisher; Janke Kleynhans

doi:10.3389/fnume.2023.1209823

Biodosimetry, can it find its way to the nuclear medicine clinic?

Front Nucl Med. 2023 Jul 25:3:1209823. doi: 10.3389/fnume.2023.1209823. eCollection 2023.

Authors

Julie Bolcaen¹, Nastassja Combrink², Kaat Spoormans³, Stuart More⁴, Charlot Vandevoorde⁵, Randall Fisher¹, Janke Kleynhans⁶

Affiliations

¹ Radiation Biophysics Division, SSC Laboratory, iThemba Laboratory for Accelerator Based Sciences (iThemba LABS), Cape Town, South Africa.
² Nuclear Medicine Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
³ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium.
⁴ Division of Nuclear Medicine, Department of Radiation Medicine, University of Cape Town, Cape Town, South Africa.
⁵ Biophysics Departement, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany.
⁶ Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, Catholic University of Leuven, Leuven, Belgium.

Abstract

Personalised dosimetry based on molecular imaging is a field that has grown exponentially in the last decade due to the increasing success of Radioligand Therapy (RLT). Despite advances in imaging-based 3D dose estimation, the administered dose of a therapeutic radiopharmaceutical for RLT is often non-personalised, with standardised dose regimens administered every 4-6 weeks. Biodosimetry markers, such as chromosomal aberrations, could be used alongside image-based dosimetry as a tool for individualised dose estimation to further understand normal tissue toxicity and refine the administered dose. In this review we give an overview of biodosimetry markers that are used for blood dose estimation, followed by an overview of their current results when applied in RLT patients. Finally, an in-depth discussion will provide a perspective on the potential for the use of biodosimetry in the nuclear medicine clinic.

Keywords: Iodine-131; [177Lu]Lu-DOTA-TATE/TOC; [177Lu]Lu-PSMA-RLT; biodosimetry and nuclear medicine; cytokinesis-block micronucleus assay (CBMN); dicentric chromosome assay (DCA); gene transcript analysis; γH2AX foci assay.

Publication types

Review